Research programme: parainfluenza virus therapies - BioCryst

Drug Profile

Research programme: parainfluenza virus therapies - BioCryst

Alternative Names: BCX-2798; Parainfluenza virus hemagglutinin-neuraminidase inhibitors - BioCryst Pharmaceuticals; Parainfluenza virus HN inhibitors - BioCryst

Latest Information Update: 11 Dec 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action HN protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parainfluenza virus infections

Most Recent Events

  • 07 Dec 2012 Discontinued - Preclinical for Parainfluenza virus infections in USA (PO)
  • 17 Apr 2008 Preclinical pharmacodynamics data presented at the 21st International Conference on Antiviral Research (ICAR-2008)
  • 02 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top